Ruxotemitide (LTX 315, Oncopore) is the oncolytic peptide that kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization.
Storage Temp
Store at -80°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description
Information
Ruxotemitide (LTX 315) Ruxotemitide (LTX 315, Oncopore) is the oncolytic peptide that kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization.
In vitro
LTX-315 is highly active against both murine and human melanoma cell lines in vitro. while displaying low EC50 cytotoxic activity against human red blood cells.LTX-315 has been shown to induce the release of ATP and HMGB1 both being DAMPs involved in ICD.
In vivo
when syngeneic B16 melanomas are treated intralesionally, a majority of the animals (~80%) treated with LTX-315 experience a complete and long-lasting tumor regression. LTX-315 injection induces an extensive hemorrhagic necrosis of the tumor parenchyma and a massive infiltration of CD3+ T cells, indicating that the peptide induces a type of cell death that leads to an increase in the number of tumor-infiltrating lymphocytes (TILs). treatment of a single tumor with LTX-315 generates a systemic anti-tumor immune response that eradicated distant lesions and prevented reoccurrence following tumor rechallenge.
This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
External Descriptors
Not available
1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.
